Skip to content
Open access

Polygenic and familial contributions to antidepressant continuation, switching, discontinuation and augmentation in the All of Us and Pharmlines cohorts

Aug 2026 · medRxiv · 0 citations
Medicine

TL;DR

Antidepressant switching partly indexes depression severity rather than drug-specific non-response alone, whereas augmentation captures cross-disorder psychiatric complexity, and familial aggregation was confined to sustained, switch-free continuation.

Abstract

Predicting antidepressant response remains a major challenge, and it is unclear whether reported polygenic associations reflect drug-specific non-response or a broader propensity for treatment modification. We analysed participants with at least one antidepressant monotherapy episode of [≥]28 days in the All of Us (AoU; n=98,357) and Pharmlines (Lifelines linked to IADB.nl; n=12,884) cohorts, comparing continuation with switching, discontinuation and augmentation (atypical antipsychotic or lithium) in relation to polygenic scores (PGS). Among individuals with recorded major depressive disorder, switching, but not discontinuation, was associated with anxiety, higher depression symptom count and stress-related measures in both cohorts. Depression PGS was associated with switching in AoU (OR=1.16 per SD, 95% CI 1.12-1.20), with a concordant nominally significant estimate in Pharmlines (OR=1.11, 1.01-1.22). In AoU, depression PGS increased progressively from continuation to switching to augmentation (per-step OR=1.18, 1.15-1.21), whereas schizophrenia and bipolar disorder PGS were selectively associated with augmentation. No PGS showed drug-class-specific associations with switching. Familial aggregation in Pharmlines was detectable for continuation, including SSRI and SNRI continuation, but not for switching or discontinuation. Antidepressant switching therefore partly indexes depression severity rather than drug-specific non-response alone, whereas augmentation captures cross-disorder psychiatric complexity, and familial aggregation was confined to sustained, switch-free continuation.

Read PDF

Similar papers

Open access Sep 2026

Beyond enrichment: pharmacogenetic heterogeneity in treatment-resistant depression.

The results indicate that TRD does not represent a single, unified PGx-predicted 'poor pharmacological responder' phenotype but instead reflects a biologically heterogeneous collection of distinct PGx profiles, and actionable PGx phenotypes are neither enriched in TRD nor associated with greater TRD severity.

B. Roberts, A. Miljevic, Lauren A. Hennessy et al. · 0 citations
Review Open access Sep 2026

The influence of pharmacogenetics on the treatment-related outcomes of antidepressants and antipsychotics in Brazil: a systematic review.

Brazilian studies report relevant gene-drug associations, but sample limitations reduce generalizability, therefore, routine pharmacogenetic testing in Brazilian psychiatric practice remains premature.

Marina Celis Teixeira, Luiz Gustavo dos Santos Lima, Carolina Dagli-Hernandez et al. · 1 citation
Open access Sep 2026

439. Polygenic stratification reveals differential response to V1b antagonism in pre-exposed patients with major depressive disorder: a post-hoc analysis of the phase 2 OLIVE trial

Abstract Background Treatment-resistant depression (TRD), a subtype of major depressive disorder (MDD) defined by suboptimal response to antidepressant treatment, represents a significant unmet medical need. Vasopressin V1b receptor modulation has emerged as a potential mechanism relevant to stress-system dysregulation...

D. Gehrlach, L. Arvastson, C. zu Eulenburg et al. · 0 citations
Review Open access Sep 2026

Depressive symptom severity is associated with prevalent stroke among US adults in a nationally representative cross sectional study

Findings highlight an association between depression severity and self-reported stroke history, and both hypertension and diabetes were strong independent predictors of self-reported stroke, while higher income (PIR) was protective.

Himanshu Sharma, K. Reeta · 0 citations
Open access Sep 2026

331. Rapid antidepressant effects of inhaled GH001 in treatment-resistant depression: results from a phase 2b, double-blind, randomized controlled trial with 6-month follow-up

GH001 was well tolerated and showed rapid, significant depressive symptom improvements in TRD, and data from the OLE indicate GH001 resulted in sustained remission over 6 months with infrequent treatments.

W. Cubała, K. Doolin, F. Ryan et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.